VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

CONy 2022 | Issues using EDSS to monitor treatment response in progressive MS

Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the assessment of treatment responses in progressive multiple sclerosis (MS). Now that treatments are available that have efficacy in progressive disease, tools are required to evaluate how individual patient’s respond to a given agent. The Kurtzke Expanded Disability Status Scale (EDSS) is often used for clinical assessment of disability in progressive MS. However, using this approach to determine treatment failure means the patient will already have faced severe deterioration as changes in EDSS occur over a long period of time. New tools are required to increase our ability to monitor treatment. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.

Disclosures

Prof. Comi has received consulting and speaking fees from Novartis, Sanofi Genzyme, Genzyme Corporation, Merck KGgA, Merck Serono SpA, Celgene Group, F. Hoffman-La Roche, Almirall SpA, Janssen.